{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:21:59Z","timestamp":1778689319525,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the China Natural Science Foundation","doi-asserted-by":"crossref","award":["No. 82073671"],"award-info":[{"award-number":["No. 82073671"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Leading Talents of Public Health in Shanghai","award":["No. GWV-10.2-XD22"],"award-info":[{"award-number":["No. GWV-10.2-XD22"]}]},{"name":"the Excellent Young Scholars of public health in Shanghai","award":["No. GWV-10.2-YQ33"],"award-info":[{"award-number":["No. GWV-10.2-YQ33"]}]},{"name":"the Construction Plan of key disciplines of Public Health system in Shanghai","award":["GWV-10.1-XK05"],"award-info":[{"award-number":["GWV-10.1-XK05"]}]},{"name":"Military Key Discipline Construction Project","award":["No.03"],"award-info":[{"award-number":["No.03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11096-022-01514-4","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T10:03:11Z","timestamp":1677492191000},"page":"622-629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database"],"prefix":"10.1007","volume":"45","author":[{"given":"Lianhui","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"1514_CR1","unstructured":"Thrombosis and Hemostasis Group, Hematology Society of Chinese Medical Association; Hemophilia Treatment Center Collaborative Network of China. [Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)]. Zhonghua Xue Ye Xue Za Zhi. 2017 May 14;38(5):364 \u2013 70."},{"issue":"1","key":"1514_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1\u201347.","journal-title":"Haemophilia"},{"issue":"3","key":"1514_CR3","doi-asserted-by":"publisher","first-page":"e241-6","DOI":"10.1111\/j.1365-2516.2011.02687.x","volume":"18","author":"K Fischer","year":"2012","unstructured":"Fischer K, Lewandowski D, Marijke van den Berg H, et al. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project. Haemophilia. 2012;18(3):e241-6.","journal-title":"Haemophilia"},{"issue":"9","key":"1514_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","volume":"57","author":"K Yoneyama","year":"2018","unstructured":"Yoneyama K, Schmitt C, Kotani N, et al. Pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase iii dose selection for emicizumab in hemophilia A. Clin Pharmacokinet. 2018;57(9):1123\u201334.","journal-title":"Clin Pharmacokinet"},{"issue":"23","key":"1514_CR5","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","volume":"130","author":"PJ Lenting","year":"2017","unstructured":"Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463\u20138.","journal-title":"Blood"},{"issue":"9","key":"1514_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809\u201318.","journal-title":"N Engl J Med"},{"issue":"2","key":"1514_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/19420862.2018.1415671","volume":"10","author":"H Kaplon","year":"2018","unstructured":"Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10(2):183\u2013203.","journal-title":"MAbs"},{"key":"1514_CR8","unstructured":"FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii#:~:text=On%20November%2016%2C%202017%2C%20the,deficiency)%20with%20factor%20VIII%20inhibitors. Accessed 02 Oct 2022."},{"key":"1514_CR9","unstructured":"FDA Grants Roche Breakthrough Therapy Designation on Hemophilia Drug. https:\/\/www.biopharminternational.com\/view\/fda-grants-roche-breakthrough-therapy-designation-hemophilia-drug. Accessed 02 Oct 2022."},{"issue":"5","key":"1514_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.615","volume":"10","author":"EM Rodriguez","year":"2001","unstructured":"Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10(5):407\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"1514_CR11","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/archinte.165.12.1363","volume":"165","author":"DK Wysowski","year":"2005","unstructured":"Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969\u20132002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363\u20139.","journal-title":"Arch Intern Med"},{"key":"1514_CR12","unstructured":"Questions. and Answers on FDA\u2019s Adverse Event Reporting System (FAERS). https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed 02 Oct 2022."},{"issue":"1","key":"1514_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1514_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1514_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57\u201369.","journal-title":"Stat Methods Med Res"},{"issue":"9","key":"1514_CR16","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/pds.3811","volume":"24","author":"J Wang","year":"2015","unstructured":"Wang J, Ye XF, Guo XJ, et al. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China. Pharmacoepidemiol Drug Saf. 2015;24(9):962\u201370.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1514_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","volume":"82","author":"JS Almenoff","year":"2007","unstructured":"Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1514_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","volume":"13","author":"K Kubota","year":"2004","unstructured":"Kubota K, Koide D, Hirai T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf. 2004;13(6):387\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"23","key":"1514_CR19","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","volume":"344","author":"PM Mannucci","year":"2001","unstructured":"Mannucci PM, Tuddenham EG. The hemophilias\u2014from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"1514_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811\u201322.","journal-title":"N Engl J Med"},{"issue":"24","key":"1514_CR21","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127\u201338.","journal-title":"Blood"},{"issue":"6","key":"1514_CR22","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"SW Pipe","year":"2019","unstructured":"Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295\u2013305.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1514_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/hae.13641","volume":"25","author":"EC Rodriguez-Merchan","year":"2019","unstructured":"Rodriguez-Merchan EC, Valentino LA. Emicizumab. Review of the literature and critical appraisal. Haemophilia. 2019;25(1):11\u201320.","journal-title":"Haemophilia"},{"issue":"3","key":"1514_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/rth2.12201","volume":"3","author":"KE Dane","year":"2019","unstructured":"Dane KE, Lindsley JP, Streiff MB, et al. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemostasis. 2019;3(3):420\u20133.","journal-title":"Res Pract Thromb Haemostasis"},{"issue":"11","key":"1514_CR25","first-page":"771","volume":"33","author":"ZP Chen","year":"2020","unstructured":"Chen ZP, Li G, Li ZK, et al. Effect of emicizumab on coagulation assays of hemophilia A. J Clin Hematol. 2020;33(11):771\u20135.","journal-title":"J Clin Hematol"},{"issue":"3","key":"1514_CR26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/hae.13990","volume":"26","author":"A Bowyer","year":"2020","unstructured":"Bowyer A, Kitchen S, Maclean R. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia. 2020;26(3):536\u201342.","journal-title":"Haemophilia"},{"issue":"3","key":"1514_CR27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1182\/blood.2020006315","volume":"137","author":"P Knoebl","year":"2021","unstructured":"Knoebl P, Thaler J, Jilma P, et al. Emicizumab for the treatment of acquired hemophilia A. Blood. 2021;137(3):410\u20139.","journal-title":"Blood"},{"key":"1514_CR28","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761083s000lbl.pdf. Accessed 02 Oct 2022."},{"issue":"10","key":"1514_CR29","first-page":"1112","volume":"22","author":"JY Li","year":"2019","unstructured":"Li JY, Zhang YK, Zhang SY, et al. A new drug for hemophilia A: emicizumab. Practical Pharm Clin Remedies. 2019;22(10):1112\u20136.","journal-title":"Practical Pharm Clin Remedies"},{"issue":"3","key":"1514_CR30","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1111\/hae.13965","volume":"26","author":"HL Hooimeijer","year":"2020","unstructured":"Hooimeijer HL, Lukens MV, Verhagen MV, et al. A boy with joint pain associated with emicizumab treatment: the importance of plasma level measurement. Haemophilia. 2020;26(3):e138\u201340.","journal-title":"Haemophilia"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01514-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01514-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T07:16:19Z","timestamp":1686208579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01514-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01514-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1623004\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1623004\/v2","asserted-by":"object"}]},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"10 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}